Fresenius medical care delivers 18% earnings growth in 2024 and continues the acceleration momentum into 2025

Organic revenue growth1 of 4% driven by care enablement and care delivery underlying u.s. same market treatment growth further accelerated in q4 and turned positive for the full year accumulated savings of the fme25 program already reached eur 567 million and 2025 target raised to eur 750 million with 18% operating income2 growth top end of the 2024 outlook range reached reported operating income grew by 2%, reported net income3 by +8% net financial leverage ratio reduced from 3.2x to 2.9x and dividend is planned to be raised by 21% high teens to high twenties percent earnings growth in 2025, translating into an 11 to 12% margin bad homburg, germany , feb. 25, 2025 /prnewswire/ -- "fresenius medical care has again delivered against its commitments and we met the top end of our 2024 target to profitably grow our business. we successfully executed against our strategic turnaround and transformation plan, advancing our legacy portfolio optimization and realizing significant fme25 savings ahead of plan.
FMS Ratings Summary
FMS Quant Ranking